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perspective was adapted and all costs were adjusted to British pounds in 2014 
value. Results: The mean survival of 311 AML patients was 1.2 years. The aver-
age inpatient costs and standard deviations over a follow-up period ranging from 
7 to 10 years were £38,532 (SD: £44,986), £32,115 (SD: £34,293), and £28,662 (SD: 
£33,298) for bottom-up costing, reference costs, and tariff costings respectively. 
These differences mainly reflect variations in first-line and second-line treatment 
costs (p< 0.001); while during remission, the cost estimates from the three meth-
ods were identical. ConClusions: This study demonstrates that costing methods 
can generate substantially different cost estimates. Hence, decision makers need 
to interpret cost outcomes cautiously, taking account of the assumptions made.
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objeCtives: In economic analyses, the size (volume per vial) of pharmaceutical 
products is usually taken as a fixed quantity. However, whilst the product is in devel-
opment, there is scope for the size to be altered. The objective of this study was to 
examine how product sizes might be optimised for maximum efficiency. Methods: 
Four drugs available in two product sizes were chosen as examples: pemetrexed, 
cetuximab, panitumumab and belimumab. Drug costs per administration were 
estimated based on general population weight and body surface area data from 
the Health Survey for England, using the most efficient combinations of the two 
available vial sizes. The sizes of the two vials were varied simultaneously to identify 
the lowest average costs achievable. Results: Generally, smaller vials were associ-
ated with less wastage and lower costs. Within the size ranges analysed, the cost 
per administration could be reduced by an average of 4.4% (range: 1.12% to 6.39%). 
Over 1 year on treatment, this represents an average potential saving of £1,892 
(range: £120 to £3,289). However, this was associated with an increased number of 
vials per dose. ConClusions: The cost effectiveness of new medicines could be 
enhanced by better planning in the manufacturing process and more efficiently 
sized vials. Costs were generally greater when the large vial was a multiple of the 
smaller vial (which is the case in three of the four example drugs). Non-divisible 
pairs are associated with more precise dosing and less wastage, as a greater number 
of unique quantities can be formed with same numbers of vials. Optimal vial sizing 
could reduce costs for health systems, improving patient access to new medicines 
as a consequence. Increases in the number of vials per dose may impact the time 
and cost of preparation, but additional costs may be offset by savings from reduc-
tions in wastage.
PRM30
MethOd cOMPaRiSOn Of cenSORing cOSt analySeS
Wang H1, Aas E2, Roman E1, Smith A1
1University of York, York, UK, 2University of Oslo, Oslo, Norway
objeCtives: Cost analysis is an essential component of health economic evalu-
ation. However, cost data are often incomplete due to loss of follow-up or admin-
istrative termination. Ignoring censored data could lead to biased cost results. 
Over the decades, many statistical methods for censored cost data have been pro-
posed. However, studies on method comparison and appropriate application in 
clinical settings are limited. The aim of this study is to compare such methods and 
assess their accuracies in a population of patients with acute myeloid leukaemia 
(AML). Methods: Data were sourced from Haematological Malignancy Research 
Network (www.hmrn.org), an established UK population-based registry, and cost 
data were derived from linked Hospital Episode Statistics (HES). All adults (≥ 18) in 
the network newly diagnosed with AML from September 2004 to August 2007 were 
included (n= 311) and followed until August 2014. Data were censored in 2008, 2010 
and 2012, accordingly cost analyses were undertaken for a minimum follow-up 
period of 1, 3 and 5 years respectively. Seven common methods were used to predict 
mean costs: naïve approaches (full-sample and uncensored cases), Lin’s 2007a, Lin’s 
2007b, Bang and Tsaitis, Lin’s regression and phase-based costing methods. All costs 
were adjusted to British pounds in 2014 value. Results: The true lifetime cost was 
£32,115 per patient. When censored in 2008, the estimate from Bang and Tsaitis 
method was the closest prediction (£30,536). When censored in 2010 and 2012, full-
case naïve and phase-based methods provided more accurate estimates (£31,486 
and £31,501 respectively). ConClusions: The study shows that cost estimations 
vary with the method chosen and the duration of follow-up in the presence of cen-
soring. Compared to the true lifetime cost, the phase-base censoring method with a 
minimum 3-year follow-up would yield the most accurate cost estimation. Further 
work on other cancers are needed to confirm the generalizability of these results.
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objeCtives: Centrifugation (Cf) is the standard method of fat processing but is 
cumbersome and time consuming, especially when large volumes are processed. A 
new autologous fat processing system (Rv) that incorporates fat harvesting and pro-
cessing in a single unit offers a simple, more efficient system. This study compared 
the efficiency and economics of using Rv with CF in terms of fat grafting and operat-
ing room (OR) costs. Methods: Data were collected over 2 years from consecutive 
breast surgery patients undergoing autologous fat grafting: January to December 
2012 with the Cf method and January to December 2013 with Rv method. The volume 
of fat harvested, volume of fat injected after processing, and time taken to complete 
fat grafting (from harvest to injection) were determined. Standard OR costs ($15-$20 
efficacy and safety profiles for published data on antidepressants fluoxetine and 
venlafaxine vs placebo and is compared to standard SMAA results. Results: The 
results showed that, with a non-informative Dirichlet prior, the posterior mean 
weights for given rankings were similar to the central weight vectors of the standard 
SMAA, so were some other comparable measures such as the rank acceptability 
index and confidence factor ConClusions: The Bayesian SMAA has a number of 
advantages inherited from Bayesian decision analysis. The Bayesian estimates for 
key SMAA measures are similar to those of the standard SMAA. But it offers more 
options and flexibilities than the standard SMAA, and its implementation is easier.
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objeCtives: The objective was to conduct a Bayesian multivariate network meta-
analysis (NMA) to take into account the correlation between three outcome meas-
ures assessing glycaemic control for the monotherapy treatments of type 2 diabetes 
mellitus (T2DM). Methods: A systematic literature review was conducted to iden-
tify relevant randomised clinical trials. The efficacy of T2DM treatments on glycae-
mic control was assessed using the change in HbA1c from baseline, the change in 
fasting plasma glucose (FPG) from baseline or the proportion of patients reaching 
HbA1c < 7%. A Bayesian multivariate NMA accounting for the correlation between 
outcomes was conducted to model these three outcomes simultaneously and results 
were compared to the estimates from the three univariate NMAs. Interpretation of 
results was based on absolute differences/ratios and surface under the cumula-
tive ranking curve (SUCRA). Results: A total of 40 studies were included in the 
analysis, all of them reported results in terms of HbA1c change from baseline, 36 
for FPG and 22 for the proportion of patients reaching HbA1c < 7%. Results for the 
analysis of glycaemic control from the multivariate NMA were overall consistent 
with the three univariate NMAs in terms of ranking of treatments based on the 
SUCRA and point estimates were comparable. Using the multivariate NMA, results 
for the proportion of patients reaching HbA1c < 7% were available for sulfonylureas, 
while no data on sulfonylureas were published for this outcome. Moreover, with the 
multivariate NMA, standard deviations were slightly lower compared to the univari-
ate ones. ConClusions: This multivariate network meta-analysis of treatments 
in T2DM provided more precise estimates than separate univariate NMAs on gly-
caemic control. It enabled estimations of treatment effect for all comparators on all 
endpoints of interest including the ones for which data were not publicly available.
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objeCtives: Indirect Treatment Comparisons (ITC) are used to contrast the effec-
tiveness of two or more treatments, and are usually undertaken in the absence of 
head-to-head information. However, these indirect comparisons are less effective 
in situations where baseline patient characteristics (e.g. age, disease duration) dif-
fer between studies. Any clinically meaningful variation in these characteristics 
between the studies should be adjusted for in the statistical analyses in order to 
arrive at less biased estimates of the treatment differences. At present, many ITCs 
use a comparison of a sponsor’s Individual Patient Data (IPD) with study-level sum-
mary information (typically means and SDs) from their competitors’ studies. Various 
methods currently exist which allow for the matching between studies of the base-
line characteristics means, but crucially not their variances. Methods: We outline 
a novel approach which allows for the matching of both means and variances across 
multiple baseline patient characteristics. Our approach involves fitting higher-order 
polynomials separately to each of the baseline parameters with the aim of estimat-
ing a single weight for each individual patient. The weighted means and variances 
of the IPD are then compared with the (target) summary-level data. Simulation 
is used in order to arrive at the combination of polynomial functions which give 
the ‘best fit’. Results: The method is highlighted with a case study of anti-VEGF 
therapies in the treatment of visual impairment due to diabetic macular edema. Our 
proposed method successfully matches both the means and variances across three 
important predictors of post-baseline changes in visual acuity. ConClusions: The 
ability to match IPD variability with study-level summary variability is critical in 
order to accurately estimate the statistical significance of treatment differences. To 
our knowledge, current comparative effectiveness methods fail to do so - our novel 
approach provides a possible solution to this problem.
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objeCtives: Cost is an essential part of health economic evaluation. However, 
no set standard for costing has been suggested/proposed yet, and the impact of 
using different methods remains unclear. The aim of this study is to compare cost 
estimates from different costing methods and assess their impacts. Methods: All 
adults (> 18) newly diagnosed with acute myeloid leukaemia between September 
2004 and August 2007 in the Haematological Malignancy Research Network (HMRN, 
www.hmrn.org, an established UK population-based registry) were included and 
followed until August 2014. Three costing methods were applied to the treatment 
pathways. One was a bottom-up costing, for which cost data were obtained directly 
from treating hospitals; and the other two were top-down costings that used refer-
ence costs and tariffs obtained from UK Hospital Episode Statistics (HES). The NHS 
